Abstract

Diabetes is known to increase susceptibility to infections, partly due to impaired granulocyte function and changes in the innate immunity. Here, we investigate the effect of diabetes, and high glucose on the expression of the antimicrobial peptide, psoriasin and the putative consequences for E. coli urinary tract infection. Blood, urine, and urine exfoliated cells from patients are studied. The influence of glucose and insulin is examined during hyperglycemic clamps in individuals with prediabetes and in euglycemic hyperinsulinemic clamped patients with type 1 diabetes. Important findings are confirmed in vivo in type 2 diabetic mice and verified in human uroepithelial cell lines. High glucose concentrations induce lower psoriasin levels and impair epithelial barrier function together with altering cell membrane proteins and cytoskeletal elements, resulting in increasing bacterial burden. Estradiol treatment restores the cellular function with increasing psoriasin and bacterial killing in uroepithelial cells, confirming its importance during urinary tract infection in hyperglycemia. In conclusion, our findings present the effects and underlying mechanisms of high glucose compromising innate immunity.

Patients with diabetes have an increased susceptibility to infections. Here the authors show that high glucose impairs innate immunity through reduced levels of the antimicrobial peptide psoriasin and impaired epithelial barrier function, resulting in an increased risk of urinary tract infection.

Details

Title
Diabetes downregulates the antimicrobial peptide psoriasin and increases E. coli burden in the urinary bladder
Author
Mohanty, Soumitra 1   VIAFID ORCID Logo  ; Kamolvit, Witchuda 1 ; Scheffschick, Andrea 2 ; Björklund, Anneli 3 ; Tovi, Jonas 4 ; Espinosa, Alexander 5 ; Brismar, Kerstin 6 ; Nyström, Thomas 7 ; Schröder, Jens M. 8   VIAFID ORCID Logo  ; Östenson, Claes-Göran 6   VIAFID ORCID Logo  ; Aspenström, Pontus 9 ; Brauner, Hanna 10 ; Brauner, Annelie 1   VIAFID ORCID Logo 

 Karolinska Institutet, Department of Microbiology, Tumor and Cell Biology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Division of Clinical Microbiology, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705) 
 Department of Medicine, Solna, Sweden (GRID:grid.24381.3c) 
 Center for Diabetes, Academic Specialist Center, Stockholm County Council, Solna, Sweden (GRID:grid.425979.4) (ISNI:0000 0001 2326 2191); Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Capio Health Care Center, Solna, Sweden (GRID:grid.4714.6) 
 Department of Medicine, Solna, Sweden (GRID:grid.4714.6) 
 Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Division of Internal Medicine, Unit for Diabetes Research, Karolinska Institutet, South Hospital, Department of Clinical Science and Education, Stockholm, Sweden (GRID:grid.4714.6) 
 University Hospital Schleswig-Holstein, Department of Dermatology, Venerology and Allergology, Kiel, Germany (GRID:grid.412468.d) (ISNI:0000 0004 0646 2097) 
 Uppsala University, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology (IGP), Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457) 
10  Department of Medicine, Solna, Sweden (GRID:grid.8993.b); Karolinska University Hospital, Dermato-Venereology Clinic, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2715913557
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.